Greenleaf Trust Buys New Position in Kenvue Inc. (NYSE:KVUE)

Greenleaf Trust bought a new stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 14,962 shares of the company's stock, valued at approximately $359,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Clarity Asset Management Inc. purchased a new stake in shares of Kenvue during the fourth quarter worth $45,000. Continuum Advisory LLC boosted its position in Kenvue by 2,071.1% during the first quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock worth $47,000 after acquiring an additional 1,864 shares during the last quarter. Rossby Financial LCC purchased a new stake in Kenvue during the 1st quarter valued at about $52,000. Golden State Wealth Management LLC grew its stake in Kenvue by 292.0% during the 1st quarter. Golden State Wealth Management LLC now owns 3,081 shares of the company's stock valued at $74,000 after acquiring an additional 2,295 shares in the last quarter. Finally, Versant Capital Management Inc raised its holdings in Kenvue by 77.9% in the 1st quarter. Versant Capital Management Inc now owns 3,415 shares of the company's stock valued at $82,000 after acquiring an additional 1,495 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Stock Performance

Shares of Kenvue stock traded up $0.43 during trading on Friday, reaching $21.35. The company's stock had a trading volume of 25,967,559 shares, compared to its average volume of 16,069,564. The company has a 50-day moving average price of $22.34 and a two-hundred day moving average price of $22.29. The firm has a market cap of $40.96 billion, a PE ratio of 38.82, a P/E/G ratio of 3.32 and a beta of 0.83. Kenvue Inc. has a fifty-two week low of $17.85 and a fifty-two week high of $25.17. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The firm had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. During the same period last year, the firm posted $0.28 EPS. Kenvue's quarterly revenue was down 3.9% on a year-over-year basis. On average, analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.84%. Kenvue's payout ratio is currently 149.09%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on KVUE. Citigroup reaffirmed a "neutral" rating on shares of Kenvue in a research note on Friday, June 13th. Redburn Atlantic assumed coverage on shares of Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target on the stock. Evercore ISI assumed coverage on Kenvue in a research report on Monday, March 24th. They issued an "in-line" rating and a $25.00 price objective for the company. Barclays raised their target price on Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a research note on Monday, May 12th. Finally, UBS Group upped their price target on Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Friday, May 9th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Kenvue presently has an average rating of "Hold" and a consensus price target of $25.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.